MedTrace Logo

Evaluating Tocilizumab for Sever COVID-19 Infection in Breast Cancer vs. Non Cancer Pateints

NCT04871854 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2022-11-01

No results posted yet for this study

Summary

To compare evaluating Clinical outcomes for patients treated with with or without breast cancer patients comorbidity for sever COVID-19 infection in breast cancer patients versus non cancer patients and evaluating Tocilizumab efficacy versus traditional therapy

Conditions

Interventions

DRUG

Tocilizumab

patients treated with Tocilizumab for Covid-19 infection

DRUG

traditional Covid -19 therapy

patients treated with traditional therapy for Covid-19 infection

Sponsors & Collaborators

  • Beni-Suef University

    lead OTHER

Principal Investigators

  • Raghda Hussein, PHD · Beni suef university fculty of pharmacy

  • Ahmed Hassan shaaban, MD · clinical oncology faculty of medicine Beni suef university

  • Doaa Mahmoud, MD · Beni-Suef University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-26
Primary Completion
2022-07-26
Completion
2022-08-26

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04871854 on ClinicalTrials.gov